Introducing the first comprehensive cfDNA and cfRNA test for clinical use

Pan-Tumor Assay for Both Solid Tumors and Hematologic Malignancies

Now more patients can receive comprehensive answers about their cancer with a test that combines targeted transcriptome and cfDNA together!

Liquid Trace® - Hematology
Liquid Trace® - Solid Tumor

GTC’s Liquid Trace® Test Overview

>300 cfDNA genes - >1600 cfRNA genes

GTC’s Liquid Trace can significantly reduce the need for bone marrow biopsies for hematology patients

GTC’s Liquid Trace® is a pan-cancer test that evaluates cell-free RNA (cfRNA) and cfDNA and provides highly informative data that can be used for diagnoses, evaluating the host immune response, and identifying biomarkers for predicting responses to various therapies. 

CSF Testing

Cerebrospinal fluid (CSF) is the most informative biofluid for liquid biopsy in CNS tumors and leptomeningeal disease because it directly bathes the brain and spinal cord, capturing tumor-derived cfDNA, cfRNA, and cells that rarely appear in peripheral blood. CSF provides higher tumor fraction, clearer mutational signals, and increased sensitivity for detecting low-volume or compartmentalized disease. This enables more accurate diagnosis, real-time monitoring of treatment response, and earlier identification of resistance or progression. CSF liquid biopsy offers a minimally invasive, comprehensive molecular profile that supports precision therapy decisions when tissue is limited or inaccessible.

Get Comprehensive Results by Combining cfRNA With cfDNA

Liquid biopsy in its current form is dependent on circulating cell-free DNA (cfDNA) analysis; this method likewise presents multiple challenges. These include variations in DNA shedding between tumors as well as low sensitivity (especially in early-stage cancer), difficulty in detecting fusion genes (i.e., chromosomal translocations leading to the expression of chimeric mRNA from two genes), and inability to reflect the numerous biological processes that modify RNA expression levels, such as alternative splicing, stability, and allele-specific methylation. The latter limitation is critically important as recent studies have shown that RNA testing provides another level of biological information regarding the tumor and its microenvironment. 

cfDNA Only Provides Partial Results

Comparison of findings from cfDNA and cfRNA

Figure 1: Comparison of findings from cfDNA and cfRNA

cfDNA Only Provides Partial Results

Figure 2: cfRNA analysis shows fusion

The Benefits of cfRNA

RNA sequencing has proven to be more sensitive in detecting mutations in clinical studies.  This research is consistent with GTC’s findings that cfRNA has increased sensitivity over cfDNA alone.  More specifically, cfRNA allows GTC’s Liquid Trace to detect mutations and fusions in hematologic and solid tumor samples that may be undetected with conventional cfDNA. 

Liquid Trace® Can Detect:

  • Chromosomal abnormalities
  • Gene amplification
  • Fusion genes
  • Gene expression
  • Alternative splicing
  • Exon skipping
  • HRR / HRD
  • HPV / EBV / TTV 
  • TMB
  • Monitor therapeutic response

Liquid Trace® also provides biomarker discovery with AI, especially for immunotherapy applications.

Larn More About Our Genomic Tests

Liquid Trace® Profiles Comparison Table

Features Liquid Trace® - Hematology Liquid Trace® - Solid Tumor
Tested Genes
>300 cfDNA / >1600 cfRNA
>300 cfDNA / >1600 cfRNA
TAT
5-7 Day
5-7 Day
Indications
All hematologic neoplasms including lymphoma multiple myeloma, acute lymphoblastic leukemia, acute myeloid leukemia, MDS, TTV, CMML, MPN, VEXAS syndrome, EBV, and HRV, HTLV1 status and quantification Chromosomal abnormalities, and gene amplifications, T- & B-cell clonality analysis Monitor therapeutic response
Chromosomal abnormalities, gene amplifications, HRR Fusions: ALK, ROS1, RET, NTRK1/2/3, and more. BRAF, CIC, EWSR1, PD-L1, MET exon 14 skipping and various alternative splicing, MET, HER2, PIK3CA, PTEN, EBV, HPV, Gene amplifications, AKT1, RAS, HER2, MYC, EGFR, TTV, HTLV-1 status, T- & B-cell clonality analysis Monitor therapeutic response
Sample Type
Peripheral blood, Plasma, CSF
Peripheral blood, Plasma, CSF
Sample Requirements
Peripheral blood: 8-10 mL.
EDTA tube preferred
CSF: 7-10 mL. Clear tubes
Peripheral blood: 8-10 mL.
EDTA tube preferred
CSF: 7-10 mL. Clear tubes
Results Reported
DNA+RNA
DNA+RNA
Clinical Utility
Monitoring
Therapeutic
Prognostic
Heterogeneity
Clinical Trial Matching
Monitoring
Therapeutic
Prognostic
Heterogeneity
Clinical Trial Matching
Learn More
Explore Test
Explore Test

Want to explore our scientific content?

Discover articles, videos, publications